Yan Fuqin, Sun Xiaomeng, Xu Chun
Department of Pharmacy, China Armed Police General Hospital, Beijing 100039, P.R. China.
Department of Endocrinology, China Armed Police General Hospital, Beijing 100039, P.R. China.
Exp Ther Med. 2018 Feb;15(2):1728-1734. doi: 10.3892/etm.2017.5537. Epub 2017 Nov 22.
Resveratrol is a flavonoid with a stilbene structure that is able to suppress acute pulmonary thromboembolism-induced pulmonary artery hypertension. Furthermore, it possesses anti-cancer and antioxidant properties, is able to regulate blood lipids and increase life expectancy. In the present study, it was evaluated whether the protective effect of resveratrol was able to improve cardiovascular function in rats with diabetes. The effects of resveratrol on blood glucose, body weight, heart/body weight ratio, plasma triglyceride levels, heart rate, aspartate transaminase (AST)/alanine transaminase (ALT) ratio and total plasma insulin were evaluated. Levels of inflammation and oxidative stress were also evaluated using ELISA kits, and the expressions of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF) and phosphorylated (p)-p38 protein were evaluated via western blot analysis. The results demonstrated that administration of resveratrol in rats with diabetes-related myocardial infarction (DRMI) significantly reduced blood glucose, body weight, plasma triglyceride levels, heart rate and AST/ALT ratio (all P<0.01) and significantly increased total plasma insulin (P<0.01). Furthermore, resveratrol significantly reduced levels of inflammation factors (P<0.01) and malondialdehyde, a marker for oxidative stress, in rats with DRMI (P<0.01). Resveratrol significantly increased the expression of eNOS (P<0.01) and suppressed the expression of VEGF and p-p38 (both P<0.01) in rats with DRMI. These results suggest that treatment with resveratrol is able to improve cardiovascular function via inhibition of eNOS and VEGF, and suppression of p38 phosphorylation in rats with DRMI.
白藜芦醇是一种具有芪类结构的黄酮类化合物，能够抑制急性肺血栓栓塞诱导的肺动脉高压。此外，它具有抗癌和抗氧化特性，能够调节血脂并延长寿命。在本研究中，评估了白藜芦醇的保护作用是否能够改善糖尿病大鼠的心血管功能。评估了白藜芦醇对血糖、体重、心脏/体重比、血浆甘油三酯水平、心率、天冬氨酸转氨酶（AST）/丙氨酸转氨酶（ALT）比值和血浆总胰岛素的影响。还使用酶联免疫吸附测定试剂盒评估了炎症和氧化应激水平，并通过蛋白质印迹分析评估了内皮型一氧化氮合酶（eNOS）、血管内皮生长因子（VEGF）和磷酸化（p）-p38蛋白的表达。结果表明，给糖尿病相关心肌梗死（DRMI）大鼠施用白藜芦醇可显著降低血糖、体重、血浆甘油三酯水平、心率和AST/ALT比值（均P<0.01），并显著增加血浆总胰岛素（P<0.01）。此外，白藜芦醇可显著降低DRMI大鼠的炎症因子水平（P<0.01）和氧化应激标志物丙二醛水平（P<0.01）。白藜芦醇可显著增加DRMI大鼠中eNOS的表达（P<0.01），并抑制VEGF和p-p38的表达（均P<0.01）。这些结果表明，白藜芦醇治疗能够通过抑制eNOS和VEGF以及抑制DRMI大鼠中的p38磷酸化来改善心血管功能。
